| Budget Amount *help |
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2005: ¥1,200,000 (Direct Cost: ¥1,200,000)
Fiscal Year 2004: ¥2,200,000 (Direct Cost: ¥2,200,000)
|
|---|
| Research Abstract |
Purpose : We previously reported the existence of p53-derived non-mutated peptides as cytotoxic T lymphocyte(CTL) epitopes in breast cancer(BC) patients(Ref.11). We also demonstrated that Ab reactive to CTL epitope peptides can be used as a laboratory marker to predict better estimate the prognosis of cancer patients receiving peptide vaccinations(Ref.14). The object of this study was to better understand the immune responses to p53-peptides in BC patients. Experimental Design : We measured anti-p53-peptides in the sera of patients with BC(n=104), prostate cancer(PC, n=50), autoimmune diseases(AI, n=50), atopic disease(AD, n=24), and healthy donors(HDs, n=83). Result : The levels of IgG specific to the p53377-385 in both BC and Al patients were significantly higher than those in AD, PC, and HDs. Significant levels of the anti-p53377-385 IgG were detected in the sera from 23% of the patients with BC, 0% with PC, 32% with AI, 4% with AD, and 5% HDs. Anti-p53377-385 activity in the sera was largely reduced by absorption with the corresponding peptide, but not with the entire p53-protein. IgG reactive to entire p53-protein was detectable in the sera from 12 BC patients(12%), and only 4 of those patients were positive for anti-p53377-385 IgG. As regards prognosis, this anti-peptide Ab did not correlate with a poor prognosis, but rather seemed to be associated with a good prognosis of these BC patients in terms of stage, invasion of tumor cells, and recurrence. Conclusions : These results may provide new insight to achieve a better understanding of the immune responses to p53 antigen at the peptide level in BC patients.
|
